Peroxitech Therapeutics

Peroxitech Therapeutics operates as a biopharmaceutical firm. Peroxitech is a biotech startup originating from the University of Pennsylvania. Our primary program is an innovative therapy for sudden lung damage. The most urgent condition for our primary candidate is acute lung injury induced by COVID-19. In these individuals, sudden lung damage is the primary cause of mortality. Our co-founders and researchers uncovered a new pathway and an original medication to address and prevent sudden lung damage.